Researcher
Gabriela Torrea
- Disciplines:Bacteriology
Affiliations
- Mycobacteriology (Research unit)
Member
From1 Oct 2021 → Today - Mycobacteriology (Research unit)
Member
From1 May 2023 → Today - Mycobacteriology (Research unit)
Member
From1 Aug 2012 → 16 Apr 2015 - Mycobacteriology (Research unit)
Member
From1 Jul 2010 → 9 Aug 2012 - Mycobacteriology (Research unit)
Member
From1 Aug 2004 → 31 Aug 2021
Publications
1 - 10 of 29
- Rifampicin resistance conferring mutations among Mycobacterium tuberculosis strains in Rwanda(2023)
Authors: Isabel Cuella Martin, Jean Claude Semuto Ngabonziza, Gabriela Torrea, Conor Meehan, Wim Mulders, Bertin Ushizimpumu, Louise De Weerdt, Jelle Keysers, Willem Bram de Rijk, Tom Decroo, et al.
Pages: 274-281 - Strain diversity and gene mutations associated with presumptive multidrug-resistant Mycobacterium tuberculosis complex isolates in northwest Ethiopia(2022)
Authors: Mebrat Ejo Kitata, Gabriela Torrea, Ermias Diro, Ayenesh Abebe, Meseret Kassa, Yilak Girma, Eyasu Tesfa, Kefialew Ejigu, Cécile Uwizeye, Florian Gehre, et al.
- Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings(2022)
Authors: Armand Van Deun, Valentin Bola, Rossin Lebeke, Michel Kayomo Kaswa, Mohamed Anwar Hossain, Mourad Gumusboga, Gabriela Torrea, Bouke de Jong, L Rigouts, Tom Decroo
- Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis(2022)
Authors: Ruth L. Goodall, Karen Sanders, Gay Bronson, Meera Gurumurthy, Gabriela Torrea, Sarah Meredith, Andrew Nunn, I. D. Rusen
Pages: 474 - Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB(2022)
Authors: D. M. Kokebu, S. Ahmed, R. Moodliar, C.Y. Chiang, Gabriela Torrea, Armand Van Deun, Ruth L. Goodall, I. D. Rusen, S. K. Meredith, A J Nunn
Pages: 753-759 - Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century(2022)
Authors: Jean Claude Semuto Ngabonziza, L Rigouts, Gabriela Torrea, Tom Decroo, Eliane Kamanzi, Pauline Lempens, Aniceth Rucogoza, Yves Mucyo Habimana, Lies Laenen, Esdras Belamo Niyigena, et al.
- Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment(2022)
Authors: Sophia B. Georghiou, Timothy C. Rodwell, Alexei Korobitsyn, Said H. Abbadi, Kanchan Ajbani, Jan-Willem Alffenaar, David Alland, Nataly Alvarez, Sonke Andres, Elisa Ardizzoni, et al.
- Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: a case report from Uganda(2021)
Authors: Willy Ssengooba, Kevin Komakech, Sharon Namiiro, Henry Byabajungu, Joanitah Nalunjogi, Winceslaus Katagira, Ivan Kimuli, Moses L Joloba, Susan Adakun, Lydia Nakiyingi, et al.
- Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial(2021)
Authors: Mebrat Ejo Kitata, Armand Van Deun, A Nunn, SEO Meredith, S. Ahmed, D. Dalai, O. Tumenbayar, B. Tsogt, P. T. Dat, D. T. M. Ha, et al.
Pages: 839-845 - Genetic diversity of the Mycobacterium tuberculosiscomplex strains from newly diagnosed tuberculosis patients in Northwest Ethiopia reveals a predominance of East-African-Indian and Euro-American lineages(2021)
Authors: Mebrat Ejo Kitata, Gabriela Torrea, Cécile Uwizeye, Meseret Kassa, Yilak Girma, Tiruzer Bekele, Yilkal Ademe, Ermias Diro, Florian Gehre, L Rigouts, et al.
Pages: 72-80